Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) rose 3.2% on Monday . The company traded as high as $2.29 and last traded at $2.27, with a volume of 84,943 shares. The stock had previously closed at $2.20.

CNAT has been the topic of a number of recent research reports. Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research note on Friday, July 1st. They set a “buy” rating on the stock. Brean Capital restated a “buy” rating and issued a $7.00 target price (down previously from $13.00) on shares of Conatus Pharmaceuticals in a research note on Monday, May 9th. Finally, FBR & Co restated a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Sunday, May 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. Conatus Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $9.66.

The stock’s 50-day moving average price is $2.13 and its 200-day moving average price is $2.19. The firm’s market capitalization is $48.05 million.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its earnings results on Thursday, May 5th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.35). During the same period in the prior year, the firm earned ($0.38) earnings per share. Equities analysts predict that Conatus Pharmaceuticals Inc. will post ($1.53) EPS for the current fiscal year.

An institutional investor recently raised its position in Conatus Pharmaceuticals stock. Jennison Associates boosted its stake in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) by 0.6% during the third quarter, according to its most recent filing with the SEC. The firm owned 659,067 shares of the biotechnology company’s stock after buying an additional 3,983 shares during the period. Jennison Associates owned about 3.32% of Conatus Pharmaceuticals worth $2,933,000 as of its most recent SEC filing.

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.